A poll carried out by Exco Intouch has suggested that mobile patient reported outcomes (Mpro) are replacing traditional technologies as the method of choice for electronic reported outcomes.
The poll demonstrated the effectiveness of mobile phone technology in clinical studies, following its recent webinar 'Moving from Epro to Mpro'.
The webinar, in collaboration with Novartis, discussed the advantages of Epro (electronic reported outcomes) using mobile phone technology, known in the industry as Mpro (mobile patient reported outcomes), to accurately capture real-time data.
The webinar detailed a case study example of the benefits of Mpro over other traditional methods of reporting.
The poll results revealed that 52 per cent of responders indicated that they would consider using Mpro in their next Ediary evaluation.
This demonstrated an acceptance of mobile solutions in the market and an increased enthusiasm for the use of mobile phone technology in patient care management.
This was reinforced by the fact that no responders discounted the use of Mpro for their future studies.
The poll results also revealed that the frequency of assessment, quality of user interface, feedback and electronic remainder features of Mpro all help influence patient compliance, which is crucial for good data quality.
The webinar highlighted that 70 per cent of the world's population own one of the five billion mobile phones in the world.
Recognising the increased use of mobile phones in every day life gives Epro sponsors a distinct advantage in data collection.
Exco Intouch said it has worked with more that 450,000 patients in 60 countries and has only needed to provide mobile phones to 646 patients, further validating the benefits of mobile phone technology in patient reported outcomes.
The benefits of Mpro were highlighted throughout the webinar, such as cost savings and increasing patient safety from eliminating the inaccuracies caused by patients not completing paper diaries as well as helping pharmaceutical companies employ a technology platform that enables patient data capture while complying with Food and Drug Administration (FDA) guidelines.
These advantages in technology demonstrated the increased validity Mpro lends to the collection and evaluation of data for pharmaceutical studies.
Exco Intouch said its mobile phone platform allows for consistent data throughout patient trials providing valid and quick response results in compliance with the recent FDA guidelines.
Maintaining the need for privacy, Mpro uses the patient's own mobile phone as an electronic data collection platform, immediately transmitting all data to a secure central server.
